(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 April 2007 (19.04.2007)

PCT

(10) International Publication Number
WO 2007/043542 A1

(51) International Patent Classification:
A61P 31/06 (2006.01) *A61K 31/496* (2006.01)
A61K 31/424 (2006.01) *A61K 45/06* (2006.01)
A61K 31/454 (2006.01)

(21) International Application Number:
PCT/JP2006/320239

(22) International Filing Date: 4 October 2006 (04.10.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2005-292461 5 October 2005 (05.10.2005) JP

(71) Applicant *(for all designated States except US)*: **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 9, Kanda Tsukasacho 2-chome, Chiyoda-ku, Tokyo, 1018535 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MATSUMOTO, Makoto** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP). **HASHIZUME, Hiroyuki** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP). **TOMISHIGE, Tatsuo** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP). **KAWASAKI, Masanori** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP). **SHIMOKAWA, Yoshihiko** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 463-10, Kagasuno, Kawauchicho, Tokushima-shi, Tokushima, 7710192 (JP).

(74) Agents: **ASAMURA, Kiyoshi** et al.; Room 331, New Ohtemachi Bldg., 2-1, Ohtemachi 2-chome, Chiyoda-ku, Tokyo, 1000004 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*


(48) Date of publication of this corrected version:
8 May 2008

(15) Information about Corrections:
see Notice of 8 May 2008
Previous Correction:
see Notice of 7 June 2007

(54) Title: ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS



(1)



(A)

(57) Abstract: The present invention provides antituberculous therapeutic drugs with a higher potency. The present invention provides also antituberculous therapeutic drugs containing oxazole compounds represented by (I) general formula (1): [wherein R^1 represents a hydrogen atom or C1-6 alkyl group, n represents an integer of 0-6, and R^2 represents general formula (A) or the like, wherein R^3 represents a phenoxy group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring) or the like], optically active forms thereof or salts thereof, and drugs (II) such as primary antituberculous drugs.

WO 2007/043542 A1